nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.01.2018 | Original Article

How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey

verfasst von: Z. Karaca, S. Yarman, I. Ozbas, P. Kadioglu, M. Akturk, F. Kilicli, H. S. Dokmetas, R. Colak, H. Atmaca, Z. Canturk, Y. Altuntas, N. Ozbey, N. Hatipoglu, F. Tanriverdi, K. Unluhizarci, F. Kelestimur

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

Data regarding pregnancies in relation to pituitary tumors are limited. The effects of pregnancy on pituitary adenomas and the effects of adenoma itself (hormonal activity, mass effects and pituitary insufficiency) and/or treatment on the ongoing gestation and developing fetus were evaluated.

Methods

The study was a retrospective study. A questionnaire involving questions regarding medical history before index gestation, history of related pregnancy, result of index gestation and postpartum follow-up of the patients was filled by the investigator in one of the eight Referral Endocrinology Centers from Turkey.

Results

One hundred and thirteen (83 prolactinoma, 21 acromegaly, 8 NFPA and 1 plurihormonal pituitary adenoma) pregnancies of 87 (60 prolactinoma, 19 acromegaly, 7 NFPA and 1 plurihormonal pituitary adenoma) patients were reviewed. The clinically important pregnancy-related tumor growth of pituitary adenomas was found to be low in previously treated adenomas. Prolactinomas were more likely to increase in size during pregnancy especially if effective prior treatment was lacking. The risk of hypopituitarism is also minimal due to pituitary adenomas during pregnancy. The results of pregnancies did not differ in patients who were on medical treatment or not for prolactinomas and acromegaly during gestation. Neural tube defect and microcephaly associated with maternal cabergoline use; Down syndrome and corpus callosum agenesis associated with maternal bromocriptine use; unilateral congenital cataract, craniosynostosis and microcephaly associated with maternal acromegaly were detected for the first time.

Conclusion

Medical treatment can be safely done stopped in patients with prolactinoma and acromegaly when pregnancy is confirmed and reinstituted when necessary. Prospective studies may help to determine the effects of medical treatment during gestation on the mother and fetus.

Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F (2010) Pregnancy and pituitary disorders. Eur J Endocrinol 162(3):453–475CrossRefPubMed

Molitch ME (2003) Pituitary tumors and pregnancy. Growth Horm IGF Res 13(Suppl A):S38–S44CrossRefPubMed

Heaney AP, Fernando M, Melmed S (2002) Functional role of estrogen in pituitary tumor pathogenesis. J Clin Investig 109(2):277–283CrossRefPubMedPubMedCentral

Molitch ME (2011) Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis? Nat Rev Endocrinol 7(5):254–255CrossRefPubMed

Bronstein MD, Paraiba DB, Jallad RS (2011) Management of pituitary tumors in pregnancy. Nat Rev Endocrinol 7(5):301–310CrossRefPubMed

Molitch ME (2015) Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Pituitary 172(5):R205–R213

Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 73(2):236–242

Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M, Lavezzari M, Nicolosi AE, Ferrero S, Landi ML, Beck-Peccoz P, Bonati M (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol (Elmsford, NY) 16(6):791–793CrossRef

Stalldecker G, Mallea-Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L, Chervin A, Danilowicz K, Diez S, Fainstein-Day P, Garcia-Basavilbaso N, Glerean M, Gollan V, Katz D, Loto MG, Manavela M, Rogozinski AS, Servidio M, Vitale NM (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13(4):345–350CrossRefPubMed

10.

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951CrossRefPubMed

11.

Kosus A, Kosus N, Turhan NO (2012) Gestational diabetes: comparison of the carpenter and the coustan thresholds with the new thresholds of Turkish women and implications of variations in diagnostic criteria. J Matern Fetal Neonatal Med 25(6):616–622CrossRefPubMed

12.

Himmetoglu O, Tiras MB, Gursoy R, Karabacak O, Sahin I, Onan A (1996) The incidence of congenital malformations in a Turkish population. Int J Gynaecol Obstet 55(2):117–121CrossRefPubMed

13.

Kurtoglu S, Hatipoglu N, Mazicioglu MM, Akin MA, Coban D, Gokoglu S, Bastug O (2012) Body weight, length and head circumference at birth in a cohort of Turkish newborns. J Clin Res Pediatr Endocrinol 4(3):132–139CrossRefPubMedPubMedCentral

14.

Tuncbilek E, Boduroglu K, Alikasifoglu M (1999) Results of the Turkish congenital malformation survey. Turk J Pediatr 41(3):287–297PubMed

15.

Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol 68(1):66–71CrossRef

16.

Samadi A, Skocic J, Rovet JF (2015) Children born to women treated for hypothyroidism during pregnancy show abnormal corpus callosum development. Thyroid 25(5):494–502CrossRefPubMed

17.

Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534CrossRefPubMed

18.

Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klinische Wochenschrift 65(17):823–827CrossRefPubMed

19.

Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14(4):228–238CrossRefPubMed

20.

Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, Pivonello R, Colao A (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98(1):372–379CrossRefPubMed

21.

Karaca Z, Kelestimur F (2011) Pregnancy and other pituitary disorders (including GH deficiency). Best Pract Res Clin Endocrinol Metab 25(6):897–910CrossRefPubMed

22.

Atmaca A, Dagdelen S, Erbas T (2006) Follow-up of pregnancy in acromegalic women: different presentations and outcomes. Exp Clin Endocrinol Diabetes 114(3):135–139CrossRefPubMed

23.

Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P (2010) Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95(10):4680–4687CrossRefPubMed

24.

Qureshi A, Kalu E, Ramanathan G, Bano G, Croucher C, Panahloo A (2006) IVF/ICSI in a woman with active acromegaly: successful outcome following treatment with pegvisomant. J Assist Reprod Genet 23(11–12):439–442CrossRefPubMedPubMedCentral

25.

Colao A, Merola B, Ferone D, Lombardi G (1997) Acromegaly. J Clin Endocrinol Metab 82(9):2777–2781CrossRefPubMed

26.

Cozzi R, Attanasio R, Barausse M (2006) Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155(2):279–284CrossRefPubMed

27.

Herman-Bonert V, Seliverstov M, Melmed S (1998) Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 83(3):727–731PubMed

28.

Grynberg M, Salenave S, Young J, Chanson P (2010) Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metab 95(10):4518–4525CrossRefPubMed

29.

Takano T, Saito J, Soyama A, Ito H, Iizuka T, Yoshida T, Nishikawa T (2006) Normal delivery following an uneventful pregnancy in a Japanese acromegalic patient after discontinuation of octreotide long acting release formulation at an early phase of pregnancy. Endocr J 53(2):209–212CrossRefPubMed

30.

Blackhurst G, Strachan MW, Collie D, Gregor A, Statham PF, Seckl JE (2002) The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Clin Endocrinol 57(3):401–404CrossRef

31.

Fassnacht M, Capeller B, Arlt W, Steck T, Allolio B (2001) Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clin Endocrinol 55(3):411–415CrossRef

32.

Cheng V, Faiman C, Kennedy L, Khoury F, Hatipoglu B, Weil R, Hamrahian A (2012) Pregnancy and acromegaly: a review. Pituitary. 15(1):59–63CrossRefPubMed

33.

Maffei P, Tamagno G, Nardelli GB, Videau C, Menegazzo C, Milan G, Calcagno A, Martini C, Vettor R, Epelbaum J, Sicolo N (2010) Effects of octreotide exposure during pregnancy in acromegaly. Clin Endocrinol 72(5):668–677CrossRef

34.

Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE (2007) Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92(9):3374–3377CrossRefPubMed

35.

Ersoy H, Sarı O, Aydoğan Ü, Akbulut H, Önge K, Yenen MC, Sağlam K (2011) Hypertensıon prevalance in pregnant women referred to the gynecology and obstetrics clinic of a faculty of medicine. Turk Nephrol Dial Transplant J 20(2):187–191CrossRef

36.

Cheng S, Grasso L, Martinez-Orozco JA, Al-Agha R, Pivonello R, Colao A, Ezzat S (2012) Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin Endocrinol 76(2):264–271CrossRef

37.

de Heide LJ, van Tol KM, Doorenbos B (2004) Pituitary apoplexy presenting during pregnancy. Neth J Med 62(10):393–396PubMed

38.

Masding MG, Lees PD, Gawne-Cain ML, Sandeman DD (2003) Visual field compression by a non-secreting pituitary tumour during pregnancy. J R Soc Med 96(1):27–28CrossRefPubMedPubMedCentral

39.

Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin N Am 35(1):99–116, viCrossRef

40.

Murata Y, Ando H, Nagasaka T, Takahashi I, Saito K, Fukugaki H, Matsuzawa K, Mizutani S (2003) Successful pregnancy after bromocriptine therapy in an anovulatory woman complicated with ovarian hyperstimulation caused by follicle-stimulating hormone-producing plurihormonal pituitary microadenoma. J Clin Endocrinol Metab 88(5):1988–1993CrossRefPubMed

Titel: How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey
verfasst von: Z. Karaca
S. Yarman
I. Ozbas
P. Kadioglu
M. Akturk
F. Kilicli
H. S. Dokmetas
R. Colak
H. Atmaca
Z. Canturk
Y. Altuntas
N. Ozbey
N. Hatipoglu
F. Tanriverdi
K. Unluhizarci
F. Kelestimur
Publikationsdatum: 01.01.2018
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 1/2018
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-017-0709-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Thyroid diseases and bone health

The diagnostic value of glycated albumin in gestational diabetes mellitus

Role of Jagged1-Notch pathway in thyroid development

Deiodinases and stem cells: an intimate relationship

Von Hippel–Lindau disease: a single gene, several hereditary tumors